Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Philadelphia chromosome-positive or BCR-ABL-positive chronic phase chronic myelogenous leukemia (CML)~  * In complete cytogenetic remission confirmed by 2 bone marrows ≥ 1 month apart~ * Minimal residual disease~* Detectable BCR-ABL transcript levels obtained \< 6 months apart AND ≤ 0.5-log lower than the lowest value obtained within the past 6 months~PATIENT CHARACTERISTICS:~* Karnofsky performance status 80-100%~* Bilirubin \< 2 times upper limit of normal (ULN)~* Creatinine \< 1.5 times ULN~* ALT and AST \< 2.5 times ULN~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~* No major surgery within the past 4 weeks~* No prior chemotherapy~* No prior immunosuppressive therapy~* No prior corticosteroids~* No prior stem cell transplantation~* No radiotherapy within the past 4 weeks~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).